The ATTAIN-MAINTAIN trial validated that patients can switch from tirzepatide to orforglipron and maintain their weight loss, establishing a potential sequential treatment paradigm: injectable first for maximum loss, then oral maintenance
has received honoraria for lectures from Novo Nordisk Pharma and Sumitomo Pharma
The acetyl-CoA can enter the tricarboxylic acid (TCA) cycle for production of reducing equivalents for oxidative phosphorylation resulting in ATP production, or may enter the ketone body synthesis pathway in the liver
According to the Summary of Product Characteristics (SmPC), semaglutide requires no dose adjustment for patients with hepatic impairment, though there is limited experience in severe hepatic impairment
Patients with reduced kidney or liver function may experience prolonged drug persistence, while those with higher body weight or different genetic profiles may clear the medication more or less efficiently
The letter should outline the specific reason whether that's a documentation gap, a BMI threshold issue, a step therapy requirement, or a formulary exclusion
